1. PARP Inhibitors

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. PARP Inhibitors: What Do We know?

5. PARP Inhibitors: What Do We Know? (cont)

6. PARP Inhibitors: What Don't We Know ?

7. SOLO-1: Study Rationale and Design[a]

8. Primary Endpoint and Other Results

9. Time to Second Progression or Death (PFS2)

10. SOLO-1 Conclusions

11. PAOLA-1: Phase 3 Trial of Olaparib Plus Bevacizumab vs Placebo Plus Bevacizumab as Maintenance Treatment in Advanced Ovarian Cancer

12. VELIA: Phase 3 Trial of Veliparib With Carboplatin and Paclitaxel as Continuous Maintenance

13. PRIMA: Phase 3 Trial of Niraparib vs Placebo as Maintenance Treatment in Advanced Ovarian Cancer

14. PARP Inhibitors as Maintenance Therapy

15. QUADRA

16. Updated Analysis of QUADRA

17. ORR in Biomarker-Defined, Response-Evaluable Population

18. Strategies for the Future

19. Randomized Phase 2 Trial Combining Cediranib and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer

20. Phase 3 NCI GY004 PFS by BRCA Status

21. NCI GY004 (Platinum Sensitive)

22. NCI GY005 (COCOS/Platinum Resistant)

23. ICON9: Randomized Trial of Cediranib and Olaparib Maintenance in Relapsed Platinum-Sensitive Ovarian Cancer

24. MEDIOLA: Phase 2 Basket Study of Olaparib + PDL1 Antibody (Durvalumab) in BRCAm-Positive Relapsed Ovarian Cancer

25. TOPACIO: Single-Arm Trial of PARP Inhibitor (Niraparib) + Anti-PDL1 (Pembrolizumab)

26. JAVELIN Ovarian 100 PARP

27. ATHENA Study Design

28. Which First-Line Trials Are Enrolling Patients?

29. Take-Home Messages

30. Take-Home Messages (cont)

31. Take-Home Messages (cont)

32. Abbreviations

33. Abbreviations (cont)